IMRN Financials: Immuron Limited AI Analysis

Home

Stock

IMRN

Financials

IMRN Financial

Immuron Limited

$0.71

2.84%

$0.01

As of today:Mar 24, 10:53:54 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$0.7

Open

$0.728

Day's Range

$0.7 - $0.728

52 week range

$0.677 - $2.39

Volume

1.8K

Avg.Volume

44.1K

Dividend yield

EPS (TTM)

-0.64

Market Cap

$5.8M

What is Immuron Limited?

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveler’s diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

IMRN Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	06/30/2025	06/30/2024	06/30/2023	06/30/2022	06/30/2021
Revenue	7	7	4	1	0	0
Revenue Growth (YoY)	17%	75%	300%	--	--	-100%
Cost of Revenue	2	2	1	0	0	0
Gross Profit	4	4	3	1	0	0
Selling, General & Admin	7	7	6	5	3	6
Research & Development	2	3	5	2	0	1
Operating Expenses	9	10	8	5	3	7
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	-4	-5	-6	-3	-2	-8
Income Tax Expense	0	0	0	0	0	0
Net Income	-4	-5	-6	-3	-2	-8
Net Income Growth	-43%	-17%	100%	50%	-75%	300%
Shares Outstanding (Diluted)	274.15	230.79	227.86	227.79	227.57	221.06
Shares Change (YoY)	20%	1%	0%	0%	3%	25%
EPS (Diluted)	-0.01	-0.02	-0.03	-0.01	-0.01	-0.03
EPS Growth	-42%	-26%	83%	33%	-67%	128%
Free Cash Flow	-4	-6	-5	-2	-3	-4
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	57.14%	57.14%	75%	100%	0%	0%
Operating Margin	-57.14%	-71.42%	-125%	-300%	0%	0%
Profit Margin	-57.14%	-71.42%	-150%	-300%	0%	0%
Free Cash Flow Margin	-57.14%	-85.71%	-125%	-200%	0%	0%
EBITDA	--	-5	-5	-3	-3	-7
EBITDA Margin	--	-71.42%	-125%	-300%	0%	0%
D&A For EBITDA	--	0	0	0	0	0
EBIT	-4	-5	-5	-3	-3	-7
EBIT Margin	-57.14%	-71.42%	-125%	-300%	0%	0%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Follow-Up Questions

What are Immuron Limited's key financial statements?



According to the latest financial statement (Form-10K), Immuron Limited has a total asset of $10, Net loss of $-5

What are the key financial ratios for IMRN?



Immuron Limited's Current ratio is 5, has a Net margin is -71.42, sales per share of $0.03.

How is Immuron Limited's revenue broken down by segment or geography?



Immuron Limited largest revenue segment is Hyper-immune Products, at a revenue of 4,902,865 in the most earnings release.For geography, Australia is the primary market for Immuron Limited, at a revenue of 3,746,363.

Is Immuron Limited profitable?



no, according to the latest financial statements, Immuron Limited has a net loss of $-5

Does Immuron Limited have any liabilities?



yes, Immuron Limited has liability of 2

How many outstanding shares for Immuron Limited?



Immuron Limited has a total outstanding shares of 233.95

Immuron Limited (IMRN) Financial

IMRN Stock Price Chart